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Drug Information Question

Question: What evidence is available on aldosterone antagonists for use in
heart failure with preserved ejection fraction?
by Vivian Loo, Pharm.D. Candidate, Class of 2014, and Laura Tsu, Pharm.D., BCPS, Midwestern University College of
Pharmacy – Glendale

Answer:
Introduction

Heart failure (HF) is primarily caused by abnormalities
in cardiac systolic or diastolic function, which dictate the
prevalence, prognosis, and pharmacotherapy used to treat
the patient. Diastolic heart failure can be referred to using
several interchangeable terms such as HF with normal ejection
fraction, diastolic dysfunction, or the newest terminology
being HF with preserved ejection fraction (HFpEF). HFpEF
is accountable for over half of HF patients and its prevalence
depends on various factors, with age being the most important
determinant. Several large, randomized, multi-center, doubleblinded trials have been conducted to create guidelines for
systolic HF treatment, which is also known as HF with
reduced ejection fraction (HFrEF). In contrast, few trials have
been published on the treatment of HFpEF.1,2 Currently, the
Heart Failure Society of America (HFSA) 2010 guidelines
recommend the use of diuretics, angiotensin-converting
enzyme inhibitors (ACEIs), angiotensin receptor blockers
(ARBs), beta-blockers, and calcium channel blockers as
possible treatments for HFpEF.3
While there are options for the treatment of HFpEF, most of
the currently suggested medications for treatment have grade
C recommendations, which are based on “expert opinion,
epidemiologic findings from observational studies, and safety
findings from large-scale use” unless specifically indicated
for a compelling indication.1,3 The lack of concrete evidence
and treatment recommendations for HFpEF signals a further
need for other therapy options, leading to the investigation of
aldosterone antagonists as a potential treatment option.
Studies have demonstrated that the mineralocorticoid
aldosterone is stimulated by angiotensin II and activates
mineralocorticoid receptors to cause sodium retention,
potassium excretion, endothelial dysfunction, vascular
inflammation, hypertrophy, and fibrosis—all mechanisms
that contribute to the pathophysiology of HF.4,5 Despite
the use of ACEIs in HF treatment, aldosterone levels may
still potentially increase, indicating that ACEIs may not
fully suppress angiotensin formation. Increased levels of
aldosterone have been associated with impaired functional
capacity, decreased ventilator response during exercise, and
an increase in cardiovascular mortality, making aldosterone
a potential target for HF treatment.5 The 2 most commonly
used aldosterone antagonists are spironolactone and
eplerenone. Spironolactone (Aldactone®) is generically
available and is a nonselective aldosterone receptor antagonist.
Its nonselectivity is associated with the adverse effect of
gynecomastia. Eplerenone (Inspra®) is a spironolactone
derivative, is not yet available as a generic, and has higher
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selectivity for the mineralocorticoid receptor with less
binding to androgen and progesterone receptors compared to
spironolactone.1,5
Aldosterone antagonists have been proven to be effective
in the treatment of HFrEF in the Randomized Aldactone
Evaluation Study (RALES) trial, demonstrating a 31%
decrease in cardiovascular mortality and a 30% risk reduction
in all-cause mortality in the spironolactone treatment group
compared to placebo. Similarly, the Eplerenone in Mild
Patients Hospitalization and Survival Study in Heart Failure
(EMPHASIS-HF) trial evaluated death from cardiovascular
causes and hospitalization for HF as the primary outcome
in which the eplerenone treatment group experienced a
significantly decreased incidence (18.3% eplerenone group
vs. 25.9% control group). The treatment group also had a
statistically significant 38% reduction in hospitalizations for
HF and demonstrated a decrease in all-cause mortality in
comparison to the control group.5 The HFSA 2010 guidelines
strongly recommend (grade A) the use of an aldosterone
antagonist for New York Heart Association (NYHA) class
IV HF with left ventricular ejection fraction (LVEF) < 35%
in addition to standard therapy classified as ACEI/ARB and
beta-blocker therapy.3 While the RALES and EMPHASIS-HF
trials have demonstrated a place for aldosterone antagonists
in HFrEF treatment, aldosterone antagonists have not been
included in HFpEF treatment guidelines yet. Spironolactone
and eplerenone have been further investigated as options for
HFpEF treatment in 3 clinical trials over the past 2 years.
Clinical Trials
The RAAM-PEF (Randomized Aldosterone Antagonism
in Heart Failure with Preserved Ejection Fraction) trial was a
randomized, double-blinded, placebo-controlled, single-center
study conducted by Deswal et al. comparing eplerenone 25-50
mg to placebo over 24 weeks in 44 patients. Investigators
determined that a sample size of 21 patients in each group
was necessary to provide 85% power with a 2-tailed α level
of 0.05 in order to detect differences in endpoints. The
primary endpoint was defined as a change in 6-minute
walk distance (6MWD) from baseline after the 24 weeks of
randomization and treatment.6 The 6MWD measures the
distance that a patient can walk on a flat, hard surface in a
period of 6 minutes to determine functional capacity and
is predictive of hospitalization rates and mortality in HF
patients.4,7 Secondary endpoints included echocardiographic
measurements of diastolic dysfunction, biomarkers such
as collagen turnover and B-type natriuretic peptide, HFrelated quality of life using the Kansas City Cardiomyopathy
Questionnaire, and NYHA class.6
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The results of this study showed an improvement in the
primary endpoint of 6MWD in both placebo and treatment
groups, although the difference was not significant (p =
0.91). Similarly, all secondary endpoints were not found
to be statistically significant with the exception of the E/E’
ratio and amino-terminal peptide of procollagen type I
(PINP) and carboxyl-terminal telopeptide of collagen type
I (CITP) biomarkers. The E/E’ ratio, which measures left
ventricular filling pressure and is regarded as the best index
for detecting diastolic dysfunction in HFpEF, was significantly
decreased in the eplerenone group (p = 0.01) compared to
the placebo group, which demonstrated an increase in the
E/E’ ratio. The PINP and CITP biomarkers evaluate collagen
turnover and are used as noninvasive markers to monitor
the regression of myocardial fibrosis. At baseline versus
24 weeks in the eplerenone group, both PINP and CITP
levels were significantly decreased (p = 0.009 and p = 0.026,
respectively). The trial concluded that although eplerenone
treatment in patients with HFpEF did not improve exercise
capacity as measured through the 6MWD test, it did result in
beneficial changes to collagen turnover and diastolic function.6
The Aldo-DHF (The Aldosterone Receptor Blockade in
Diastolic Heart Failure) trial was a randomized, doubleblinded, placebo-controlled, prospective, multi-center trial
conducted by Edelmann et al. comparing spironolactone to
placebo. Four hundred thirty-three patients were randomized
to receive spironolactone 25 mg or placebo and were followed
for approximately 12 months. Type I and II error rates
were set at 0.05 (α) and 0.1 (β), respectively, with a power
of 90% and an estimated sample size of 420 patients. The
co-primary endpoints compared spironolactone therapy
to placebo on diastolic function (E/E’ ratio) and maximal
exercise capacity (peak VO2) during cardiopulmonary
exercise testing in patients with HFpEF. Peak VO2 was
defined by the study as the maximum value of the last three
10-second averages during exercise. Secondary endpoints
included echocardiographic measures of cardiac function
and remodeling, submaximal and maximal exercise capacity,
serum biomarkers, quality of life, morbidity, and mortality.4
The results of the Aldo-DHF trial showed an improvement
in the primary endpoint of diastolic dysfunction as measured
by the E/E’ ratio. Echocardiographic results of the treatment
group showed a decrease in the E/E’ ratio after 12 months
compared to placebo (95% CI, -2.0 to -0.9, p < 0.001). The
primary endpoint of maximal exercise capacity did not differ
significantly between the treatment and placebo group after
12 months (p = 0.81). Other secondary endpoints of note
in the spironolactone group versus placebo group included
an increase in LVEF (95% CI, 0.1 to 3.1, p = 0.04), increase
in 6MWD (95% CI, -27 to -2, p = 0.02), decrease in left
ventricular mass index (95% CI, -10 to -1, p = 0.009), and
decrease in left ventricular end diastolic diameter (95%
CI, -2.5 to -0.3, p = 0.01). The study also acknowledged
that it was not adequately powered to assess the secondary
endpoints of morbidity and mortality. The trial concluded
that spironolactone treatment in HFpEF patients improved
diastolic function and left ventricular function but had no

effect on maximal exercise capacity.4
The clinical study TOPCAT (Treatment Of Preserved
Cardiac Function Heart Failure with an Aldosterone
Antagonist) is a multi-center, international, randomized,
double-blinded, placebo-controlled trial using 15-45 mg of
spironolactone. The study was conducted with 3,445 subjects
aged 50 years or older, recruited from over 200 clinical
centers, with HF and LVEF ≥ 45%, HFpEF, controlled systolic
blood pressure, and a serum potassium < 5.0 mEq/L. The
primary endpoint was a composite of cardiovascular mortality,
aborted cardiac arrest, or hospitalization for the management
of HF. Secondary endpoints included all-cause mortality, new
onset of diabetes mellitus or atrial fibrillation, and quality of
life. The study ended in January of 2012 and the results are
expected to be published in the near future.8
Discussion
The RAAM-PEF and Aldo-DHF trials found that
aldosterone antagonist use in patients with HFpEF improved
diastolic dysfunction as measured by the E/E’ ratio. However,
according to the Aldo-DHF trial, there is currently no accepted
minimal clinically important difference in E/E’ that should be
achieved to alter the prognosis of HFpEF.4 Both trials also
studied exercise capacity as measured by the 6MWD. The
RAAM-PEF trial, which evaluated patients after 6 months
of therapy, did not find a statistically significant difference
between the eplerenone and placebo group while the AldoDHF trial, which evaluated patients after 12 months, found
a marked improvement in the spironolactone group. The
difference in these results may be attributed to the length
of the 2 trials in which the RAAM-PEF trial may not have
had adequate time for eplerenone to exert a clinical effect
on 6MWD. It is also important to note that the RALES and
EMPHASIS-HF trials evaluated aldosterone antagonists in
HFrEF patients through the primary outcomes of differences
in morbidity and mortality. In contrast, the RAAM-PEF
and Aldo-DHF trials were only able to evaluate surrogate
markers of morbidity and mortality in HFpEF such as diastolic
function and exercise capacity.
In addition, the populations in both trials consisted mainly
of NYHA class II patients. Therefore, the results of these
studies may not be generalizable to sicker populations in the
NYHA class III and IV categories. Also, RAAM-PEF was
studied at the Veterans Affairs Medical Center in Houston,
Texas, and all but 3 patients were male, indicating that the
results are most applicable to men.
There is also concern with the risk of hyperkalemia
because a major adverse effect of aldosterone antagonists
is an elevation in potassium levels. Most, if not all, HF
patients’ medication lists include an ACEI/ARB to prevent
cardiac remodeling. The combination of an ACEI/ARB with
an aldosterone antagonist may potentially increase the risk
of an elevated potassium level leading to hyperkalemia and
subsequent arrhythmias. In both trials, a nonstatistically
significant difference was found between groups in the
development of hyperkalemia, defined as a serum potassium ≥
5.5 mEq/L.3,5 Thus, it can be concluded that with appropriate
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and routine laboratory monitoring of serum potassium levels,
aldosterone antagonists can be safely used in HFpEF patients
who are on concurrent ACEI/ARB therapy.
Based on the evidence provided by RAAM-PEF and
AldoDHF, an aldosterone antagonist may be a potential
additive therapy for HFpEF if the patient’s blood pressure
and heart rate are controlled and serum potassium levels
are carefully monitored. While these trials have shown
improvement in diastolic function and potential increases in
exercise capacity, the effects of aldosterone antagonists on
the long-term morbidity and mortality of HFpEF patients still
remains to be seen as investigated through the TOPCAT trial.
The results of the TOPCAT trial will provide more evidence
about aldosterone antagonist use in HFpEF due to its clinical
endpoints.
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